CU Boulder spinout Inscripta has now accumulated more than $259m from investors including Institut Mérieux, and will use the capital to further expand its genome engineering platform.
Inscripta, a US-based genome engineering platform developer spun out of University of Colorado, Boulder, has collected $125m in a series D round led by venture capital firm Paladin Capital Group.
Investment firm JS Capital Management and growth equity fund Oak HC/FT also took part in the round, along with unnamed existing shareholders.
Founded in 2015 as Muse Biotechnology, Inscripta has built a fully automated gene editing platform dubbed Onyx Digital Genome Engineering, which enables researchers to build libraries of millions of engineered cells in a single experiment.
The benchtop platform includes software, assays, specialised enzymes and reagents. It is aimed at areas such as healthcare, genome discovery and bioindustrial materials development and manufacturing.
The cash injection will accelerate the commercialisation of Onyx and an expansion of its applications. It increased Inscripta’s total equity financing to nearly $260m.
The company closed its $106m series C round…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
